Literature DB >> 29435814

Alterations in Gene and Protein Expression of Cannabinoid CB2 and GPR55 Receptors in the Dorsolateral Prefrontal Cortex of Suicide Victims.

María S García-Gutiérrez1,2, Francisco Navarrete1,2, Gemma Navarro3,4, Irene Reyes-Resina3,4, Rafael Franco3,4, Jose Luis Lanciego4,5, Salvador Giner6, Jorge Manzanares7,8.   

Abstract

Recent studies point to the cannabinoid CB2 receptors (CB2r) and the non-cannabinoid receptor GPR55 as potential key targets involved in the response to stress, anxiety, and depression. Considering the close relationship between neuropsychiatric disorders and suicide, the purpose of this study was to evaluate the potential alterations of CB2r and GPR55 in suicide victims. We analyzed gene and protein expression of both receptors by real-time PCR and western blot, respectively, in the dorsolateral prefrontal cortex (DLPFC) of 18 suicide victims with no clinical psychiatric history or treatment with anxiolytics or antidepressants, and 15 corresponding controls. We used in situ proximity ligation assay to evaluate whether the receptors formed heteromeric complexes and to determine the expression level of these heteromers, also assessing the co-expression of heteromers in neurons, astroglia, or microglia cells. CB2r and GPR55 gene expressions were significantly lower (by 33 and 41%, respectively) in the DLPFC of suicide cases. CB2r protein expression was higher, as were CB2-GPR55 heteroreceptor complexes. The results also revealed the presence of CB2-GPR55 receptor heteromers in both neurons and astrocytes, whereas microglial cells showed no expression. We did not observe any significant alterations of GPR55 protein expression. Additional studies will be necessary to evaluate if these alterations are reproducible in suicide victims diagnosed with different psychiatric disorders. Taken together, the results suggest that CB2r and GPR55 may play a relevant role in the neurobiology of suicide.

Entities:  

Keywords:  CB2r; Dorsolateral prefrontal cortex; GPR55; Gene expression; In situ proximity ligation assay; Suicide

Mesh:

Substances:

Year:  2018        PMID: 29435814      PMCID: PMC6095782          DOI: 10.1007/s13311-018-0610-y

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  60 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Species differences in cannabinoid receptor 2 (CNR2 gene): identification of novel human and rodent CB2 isoforms, differential tissue expression and regulation by cannabinoid receptor ligands.

Authors:  Q-R Liu; C-H Pan; A Hishimoto; C-Y Li; Z-X Xi; A Llorente-Berzal; M-P Viveros; H Ishiguro; T Arinami; E S Onaivi; G R Uhl
Journal:  Genes Brain Behav       Date:  2009-06-03       Impact factor: 3.449

3.  Chronic blockade of cannabinoid CB2 receptors induces anxiolytic-like actions associated with alterations in GABA(A) receptors.

Authors:  María S García-Gutiérrez; Borja García-Bueno; Silvia Zoppi; Juan C Leza; Jorge Manzanares
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

4.  Requirement of cannabinoid receptor type 1 for the basal modulation of hypothalamic-pituitary-adrenal axis function.

Authors:  Daniela Cota; Michel-Alexander Steiner; Giovanni Marsicano; Cristina Cervino; James P Herman; Yvonne Grübler; Johanna Stalla; Renato Pasquali; Beat Lutz; Günter K Stalla; Uberto Pagotto
Journal:  Endocrinology       Date:  2006-12-28       Impact factor: 4.736

Review 5.  Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain.

Authors:  Emmanuel S Onaivi; Hiroki Ishiguro; Jian-Ping Gong; Sejal Patel; Alex Perchuk; Paul A Meozzi; Lester Myers; Zoila Mora; Patricia Tagliaferro; Eileen Gardner; Alicia Brusco; Babatunde E Akinshola; Qing-Rong Liu; Bruce Hope; Shinya Iwasaki; Tadao Arinami; Lindsey Teasenfitz; George R Uhl
Journal:  Ann N Y Acad Sci       Date:  2006-08       Impact factor: 5.691

6.  Screening genetic variability at the CNR1 gene in both major depression etiology and clinical response to citalopram treatment.

Authors:  Marina Mitjans; Alessandro Serretti; Chiara Fabbri; Cristóbal Gastó; Rosa Catalán; Lourdes Fañanás; Bárbara Arias
Journal:  Psychopharmacology (Berl)       Date:  2013-02-14       Impact factor: 4.530

7.  Genetic association analysis of CNR1 and CNR2 polymorphisms with schizophrenia in a Korean population.

Authors:  Joon Seol Bae; Jason Yongha Kim; Byung-Lae Park; Jeong-Hyun Kim; Bomi Kim; Chul Soo Park; Bong-Jo Kim; Cheol-Soon Lee; Migyung Lee; Woo Hyuk Choi; Tae-Min Shin; Jaeuk Hwang; Hyoung Doo Shin; Sung-Il Woo
Journal:  Psychiatr Genet       Date:  2014-10       Impact factor: 2.458

Review 8.  Cannabidiol as a Potential Treatment for Anxiety Disorders.

Authors:  Esther M Blessing; Maria M Steenkamp; Jorge Manzanares; Charles R Marmar
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

9.  Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study.

Authors:  M Herkenham; A B Lynn; M R Johnson; L S Melvin; B R de Costa; K C Rice
Journal:  J Neurosci       Date:  1991-02       Impact factor: 6.167

10.  The L-α-lysophosphatidylinositol/GPR55 system and its potential role in human obesity.

Authors:  José María Moreno-Navarrete; Victoria Catalán; Lauren Whyte; Adenis Díaz-Arteaga; Rafael Vázquez-Martínez; Fernando Rotellar; Rocío Guzmán; Javier Gómez-Ambrosi; Marina R Pulido; Wendy R Russell; Mónica Imbernón; Ruth A Ross; María M Malagón; Carlos Dieguez; José Manuel Fernández-Real; Gema Frühbeck; Ruben Nogueiras
Journal:  Diabetes       Date:  2011-12-16       Impact factor: 9.461

View more
  24 in total

Review 1.  Endocannabinoid signaling pathways: beyond CB1R and CB2R.

Authors:  Roger Gregory Biringer
Journal:  J Cell Commun Signal       Date:  2021-05-12       Impact factor: 5.782

2.  Recent Advances in the Potential of Cannabinoids for Neuroprotection in Alzheimer's, Parkinson's, and Huntington's Diseases.

Authors:  Catalina Pérez-Olives; Rafael Rivas-Santisteban; Jaume Lillo; Gemma Navarro; Rafael Franco
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 3.  Progress in brain cannabinoid CB2 receptor research: From genes to behavior.

Authors:  Chloe J Jordan; Zheng-Xiong Xi
Journal:  Neurosci Biobehav Rev       Date:  2019-01-03       Impact factor: 8.989

Review 4.  Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders.

Authors:  Daniela Navarro; Ani Gasparyan; Francisco Navarrete; Abraham B Torregrosa; Gabriel Rubio; Marta Marín-Mayor; Gabriela B Acosta; Maria Salud Garcia-Gutiérrez; Jorge Manzanares
Journal:  Int J Mol Sci       Date:  2022-04-26       Impact factor: 6.208

Review 5.  Modulation of Endocannabinoid System Components in Depression: Pre-Clinical and Clinical Evidence.

Authors:  Uri Bright; Irit Akirav
Journal:  Int J Mol Sci       Date:  2022-05-15       Impact factor: 6.208

6.  Cannabinoid CB1 Receptor Involvement in the Actions of CBD on Anxiety and Coping Behaviors in Mice.

Authors:  Amaya Austrich-Olivares; María Salud García-Gutiérrez; Lucía Illescas; Ani Gasparyan; Jorge Manzanares
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-13

7.  Targeting CB1 and GPR55 Endocannabinoid Receptors as a Potential Neuroprotective Approach for Parkinson's Disease.

Authors:  Eva Martínez-Pinilla; David Aguinaga; Gemma Navarro; Alberto J Rico; Julen Oyarzábal; Juan A Sánchez-Arias; José Luis Lanciego; Rafael Franco
Journal:  Mol Neurobiol       Date:  2019-01-28       Impact factor: 5.590

Review 8.  Exo- and Endo-cannabinoids in Depressive and Suicidal Behaviors.

Authors:  Srinagesh Mannekote Thippaiah; Sloka S Iyengar; K Yaragudri Vinod
Journal:  Front Psychiatry       Date:  2021-04-23       Impact factor: 4.157

Review 9.  Integrating Endocannabinoid Signalling In Depression.

Authors:  Tarapati Rana; Tapan Behl; Aayush Sehgal; Vineet Mehta; Sukhbir Singh; Ravinder Kumar; Simona Bungau
Journal:  J Mol Neurosci       Date:  2021-01-20       Impact factor: 3.444

Review 10.  Endocannabinoid-mediated neuromodulation in the main olfactory bulb at the interface of environmental stimuli and central neural processing.

Authors:  Thomas Heinbockel; Naina Bhatia-Dey; Vonnie D C Shields
Journal:  Eur J Neurosci       Date:  2021-04-02       Impact factor: 3.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.